Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status

被引:134
作者
Gillen, D
Wirz, AA
Ardill, JE
McColl, KEL [1 ]
机构
[1] Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland
[2] Queens Univ Belfast, Dept Med, Belfast, Antrim, North Ireland
关键词
D O I
10.1016/S0016-5085(99)70118-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: There have been conflicting reports regarding acid secretion after treatment with omeprazole. This study examined acid secretion after treatment with omeprazole and its relation to Helicobacter pylori status and on-treatment gastric function. Methods: Twelve H. pylori-negative and 9 H. pylori-positive subjects were examined before, on, and at day 15 after an 8-week course of 40 mg/day omeprazole. On each occasion, plasma gastrin, intragastric pH, and acid output were measured basally and in response to increasing doses of gastrin 17. Results: In the H. pylori-negative subjects at day 15 after omeprazole treatment, basal acid output was 82% higher (P < 0.007) and maximal acid output 28% higher (P < 0.003) than before omeprazole. The degree of increase in maximal acid output was related to both on-treatment pH and on-treatment fasting gastrin levels, being 48.0% in;subjects with an on-treatment pH of >4 vs. 21.0% in those with a pH of <4 (P < 0.02) and 49.2% in subjects with an on-treatment gastrin of >25 ng.L-1 vs. 19.8% in those with a fasting gastrin of <25 ng.L-1 (P < 0.006). At day 15 after omeprazole treatment, the H. pylori-positive subjects showed a heterogeneous response with some having increased acid output and others persisting suppression. Conclusions: Rebound acid hypersecretion occurs in H. pylori-negative subjects after omeprazole treatment. Its severity is related to the degree of elevation of pH on treatment. Persisting suppression of acid secretion masks the phenomenon in H. pylori-positive subjects.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 69 条
[1]  
[Anonymous], GASTROENTEROLOGY S
[2]  
BARDHAN KD, 1995, ALIMENT PHARM THER, V9, P15
[3]   INTERACTION OF HELICOBACTER-PYLORI AND ITS FATTY-ACIDS WITH PARIETAL-CELLS AND GASTRIC H+/K+-ATPASE [J].
BEIL, W ;
BIRKHOLZ, C ;
WAGNER, S ;
SEWING, KF .
GUT, 1994, 35 (09) :1176-1180
[4]  
BELL NJ, 1993, GASTROENTEROLOGY, V104, pA41
[5]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[6]   ROLE OF GASTRIC-ACID SUPPRESSION IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
HUNT, RH .
GUT, 1992, 33 (01) :118-124
[7]   DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].
BLACK, JW ;
PARSONS, EM ;
DURANT, CJ ;
DUNCAN, WAM ;
GANELLIN, CR .
NATURE, 1972, 236 (5347) :385-&
[8]   STUDIES OF ISOLATED PARIETAL AND ENTEROCHROMAFFIN-LIKE CELLS FROM THE RAT [J].
BRENNA, E ;
WALDUM, HL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (12) :1295-1306
[9]   Multivariate analysis of pathophysiological factors in reflux oesophagitis [J].
Cadiot, G ;
Bruhat, A ;
Rigaud, D ;
Coste, T ;
Vuagnat, A ;
Benyedder, Y ;
Vallot, T ;
LeGuludec, D ;
Mignon, M .
GUT, 1997, 40 (02) :167-174
[10]   PHARMACOLOGY AND TOXICOLOGY OF OMEPRAZOLE WITH SPECIAL REFERENCE TO THE EFFECTS ON THE GASTRIC-MUCOSA [J].
CARLSSON, E ;
LARSSON, H ;
MATTSSON, H ;
RYBERG, B ;
SUNDELL, G .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1986, 21 :31-38